DBV Technologies (DBVT) Competitors $7.79 +0.47 (+6.42%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DBVT vs. CDXC, NUVB, ABCL, CVAC, XNCR, PRTA, REPL, ABUS, VECT, and KALVShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include ChromaDex (CDXC), Nuvation Bio (NUVB), AbCellera Biologics (ABCL), CureVac (CVAC), Xencor (XNCR), Prothena (PRTA), Replimune Group (REPL), Arbutus Biopharma (ABUS), VectivBio (VECT), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. ChromaDex Nuvation Bio AbCellera Biologics CureVac Xencor Prothena Replimune Group Arbutus Biopharma VectivBio KalVista Pharmaceuticals DBV Technologies (NASDAQ:DBVT) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Which has more risk & volatility, DBVT or CDXC? DBV Technologies has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, ChromaDex has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Does the media prefer DBVT or CDXC? In the previous week, DBV Technologies had 5 more articles in the media than ChromaDex. MarketBeat recorded 6 mentions for DBV Technologies and 1 mentions for ChromaDex. ChromaDex's average media sentiment score of 0.00 beat DBV Technologies' score of -0.06 indicating that ChromaDex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ChromaDex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is DBVT or CDXC more profitable? ChromaDex has a net margin of 1.62% compared to DBV Technologies' net margin of -815.73%. ChromaDex's return on equity of 4.85% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-815.73% -106.07% -76.17% ChromaDex 1.62%4.85%2.70% Do analysts rate DBVT or CDXC? DBV Technologies currently has a consensus target price of $22.50, indicating a potential upside of 188.83%. ChromaDex has a consensus target price of $9.03, indicating a potential upside of 0.00%. Given DBV Technologies' higher possible upside, equities research analysts clearly believe DBV Technologies is more favorable than ChromaDex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ChromaDex 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in DBVT or CDXC? 71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 15.4% of ChromaDex shares are owned by institutional investors. 1.9% of DBV Technologies shares are owned by company insiders. Comparatively, 9.6% of ChromaDex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community favor DBVT or CDXC? ChromaDex received 148 more outperform votes than DBV Technologies when rated by MarketBeat users. Likewise, 64.83% of users gave ChromaDex an outperform vote while only 54.22% of users gave DBV Technologies an outperform vote. CompanyUnderperformOutperformDBV TechnologiesOutperform Votes40554.22% Underperform Votes34245.78% ChromaDexOutperform Votes55364.83% Underperform Votes30035.17% Which has higher valuation & earnings, DBVT or CDXC? ChromaDex has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV Technologies$15.73M10.19-$72.73M-$5.00-1.56ChromaDex$99.60M0.00-$4.94M$0.10N/A SummaryChromaDex beats DBV Technologies on 13 of the 16 factors compared between the two stocks. Remove Ads Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$160.23M$2.90B$5.35B$7.58BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-1.7330.3721.7517.78Price / Sales10.19438.19380.5194.51Price / CashN/A168.6838.1534.64Price / Book1.073.456.433.99Net Income-$72.73M-$72.06M$3.20B$247.24M7 Day Performance9.10%8.60%9.08%8.29%1 Month Performance59.96%-17.45%-6.04%-5.37%1 Year Performance11.99%-29.74%10.66%-0.24% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies2.6086 of 5 stars$7.79+6.4%$22.50+188.8%+12.2%$160.23M$15.73M-1.7380Earnings ReportAnalyst ForecastShort Interest ↑Gap UpCDXCChromaDex2.2672 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Analyst ForecastNUVBNuvation Bio2.4417 of 5 stars$1.81+8.7%$8.75+384.8%-31.8%$611.32M$7.87M-0.8360Positive NewsHigh Trading VolumeABCLAbCellera Biologics2.1057 of 5 stars$2.05-1.9%$7.00+241.5%-43.8%$610.88M$28.83M-3.36500Gap UpHigh Trading VolumeCVACCureVac3.3307 of 5 stars$2.65+2.3%$10.00+277.4%+12.4%$593.28M$543.28M4.82880Earnings ReportShort Interest ↑XNCRXencor3.4901 of 5 stars$8.37-3.7%$34.38+310.7%-56.3%$589.77M$110.49M-2.62280PRTAProthena3.5339 of 5 stars$10.84-0.2%$55.00+407.4%-55.3%$583.49M$135.16M-4.71130Positive NewsGap UpHigh Trading VolumeREPLReplimune Group3.5992 of 5 stars$7.49+0.4%$19.43+159.4%+5.2%$576.84MN/A-2.44210Positive NewsGap UpABUSArbutus Biopharma1.742 of 5 stars$3.01-6.8%$5.50+82.7%+12.7%$576.36M$6.17M-7.0090Positive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeKALVKalVista Pharmaceuticals4.108 of 5 stars$11.50+7.4%$24.83+115.9%+0.5%$571.73MN/A-3.16100Gap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies ChromaDex Alternatives Nuvation Bio Alternatives AbCellera Biologics Alternatives CureVac Alternatives Xencor Alternatives Prothena Alternatives Replimune Group Alternatives Arbutus Biopharma Alternatives VectivBio Alternatives KalVista Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DBVT) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DBVT Stock Free DBVT Stock Alerts